buparvaquone has been researched along with Leishmaniasis, Visceral in 7 studies
*Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Croft, SL; Garnier, T; Järvinen, T; Koskinen, A; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J | 1 |
| Lehto, VP; Mondal, S; Näkki, S; Närvänen, A; Nissinen, T; Rantanen, J; Riikonen, J; Thapa, R | 1 |
| Bolás-Fernández, F; Dea-Ayuela, MA; Lalatsa, A; Mauger, M; Serrano, DR; Smith, L | 1 |
| Colombo, FA; Pereira-Chioccola, VL; Reimão, JQ; Tempone, AG | 1 |
| Croft, SL; Garnier, T; Järvinen, T; Juvonen, R; Kendrick, H; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J | 1 |
| Brown, M; Croft, S; Garnier, T; Järvinen, T; Lawrence, J; Mäntylä, A | 1 |
| Croft, SL; Furtado Campos, JH; Miles, MA; Vexenat, JA | 1 |
7 other study(ies) available for buparvaquone and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
Topics: Administration, Oral; Administration, Topical; Alkaline Phosphatase; Animals; Antiprotozoal Agents; Cricetinae; Female; Humans; Hydrolysis; In Vitro Techniques; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Naphthoquinones; Organophosphates; Permeability; Prodrugs; Skin; Solubility; Water | 2004 |
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Drug Carriers; Female; Hordeum; Injections, Intraperitoneal; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Silicon | 2021 |
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Biological Availability; Cell Line; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Emulsions; Excipients; Feasibility Studies; Humans; Leishmania infantum; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Solubility; Treatment Outcome | 2018 |
Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cells, Cultured; Cricetinae; Disease Models, Animal; Humans; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Macaca mulatta; Macrophages, Peritoneal; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Naphthoquinones; Phosphatidylserines | 2012 |
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Magnetic Resonance Spectroscopy; Microsomes, Liver; Molecular Structure; Naphthoquinones; Oximes; Rats; Rats, Wistar | 2004 |
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Female; Leishmania donovani; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Naphthoquinones; Prodrugs; Skin | 2007 |
Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Injections, Intramuscular; Leishmaniasis, Visceral; Male; Naphthoquinones | 1998 |